|Subject:||RX for Investors|
|Date:||Thu, 9 Aug 2001 00:45:03 -0500|
Please read our disclaimer on this profile on Samaritan.
July 30, 2001
Congratulations to subscribers who heeded our last three feature companies, you would have realized an average gain of 63% within four weeks of our profile date. If you are a new subscriber, please click here to sign up.
SAMARITAN PHARMECUTICALS (OTC/BB: SPHC)
Market News: INVESTORS SEEK SHELTER IN BIOTECHS
CONSIDERED SAFE HAVEN
Less short-term risk seen in sector's large-cap stocks
A barrage of bad news from technology companies has investors running for cover and many are finding it in the biotech sector. During the past month and a half, the Amex Biotech index has jumped 23%. During the same period the Toronto Stock Exchange's biotech subindex has moved up just 5%, ending the session yesterday at 2546.96. But in the context of the current market, that's not bad at all.
Technology stocks have been slumping in the wake of earnings warnings. As a result, many investors are looking elsewhere for a positive return. Lots of non-traditional (investors) are buying biotech shares, according to comments from several fund managers. This has provided the biotech companies to take advantage of the favorable climate and raise additional funds to progress their research. One of the main reasons for the phenomenon is that with its promise of blockbuster drugs, biotech offers similar rewards to technology stocks but, at least in the short term, fewer risks. Shares in biotech companies experience an even bigger up draft in March 2000, when technology shares began their meltdown. This time the bounce is less pronounced but insiders believe it may be more sustained. Since most biotechs are still at the development stage, industry analysts tend to not place a great deal of importance on the bottom line. Instead they focus on issues such as whether research and development targets are being met and the number of deals struck with major partners.
As often happens, most of the news driving the sector is coming out of U.S. based companies. Most notable company is SAMARITAN PHARMECUTICALS (OTC/BB: SPHC) that became the leader in very early detection of breast cancer yesterday by obtaining an exclusive right to the patent from Georgetown University.
The deal with Georgetown University puts SAMARITAN in the forefront of cancer detection procedures. Early detection breast cancer patent license by SAMARITAN identifies Protein (PBR) responsible for part of cellular changes in the development and progression of breast cancer. Eight years of extensive research will serve as a major breakthrough in early breast cancer detection saving many lives.
The patented procedure, entitled, "Peripheral-type Benzodiazepine Receptor is a tool for Detection, Diagnosis, Prognosis, and Treatment of Human Breast Cancer. The procedure identifies a protein named Peripheral-type Benzodiazepine receptor (PBR) to be responsible for part of the changes in cellular and molecular functions in the development and progression of breast cancer.
Why Consider Samaritan Pharmaceuticals:
- Samaritan Pharmaceuticals is a biopharmaceutical company focused on drug discovery in the key markets of Neurology, (Alzheimer's, Parkinson's) Oncology and HIV. Samaritan's proprietary drug, AnticortTM is scheduled to complete FDA Phase Ib/IIa clinical human trials for HIV this year. Samaritan has research collaboration with Georgetown University to develop its pipeline of innovation.
- One of Samaritan's drugs, AnticortTM is in FDA Phase 2 clinical trials for HIV and Samaritan hopes to submit these results to the FDA before the end of 2001. Samaritan's Brazilian AnticortTM clinical trial decreased the mortality rate of HIV patients from the norm of 60.9% to 17% over an 18-month clinical trial. In Samaritan's Romanian AnticortTM clinical trial for children with AIDS, the government requested the placebo (sugar pill) children be put on AnticortTM due to mortality concerns Samaritan has several advantages with this drug. Since there are over 36 million people living in the world with HIV, most of them in Africa, with 12 million living in the US. Samaritan's drug AnticortTM is estimated to be cost about $100 per month for treatment in the US compared to the average cost of over $700 a month and Samaritan believes the World Bank and UN AIDS will embrace AnticortTM because of its affordability where even at discounted prices the volume of sales would be extraordinary.
- SAMARITAN PHARMACEUTICALS and GEORGETOWN UNIVERSITY signed seven-year research collaboration and licensing arrangement, which began on July 1, 2001. Samaritan signed this Strategic Alliance with Georgetown University to develop "pipeline of new technology" in Memory Disorders, Alzheimer's, Cancer, HIV and Parkinson's with markets over $300 billion. This is a very important endorsement on where Samaritan is heading.
- As a result of Georgetown University partnership, two major news announcements have followed. First announcement was granting of an Exclusive Worldwide License for 'Early Detection' of Alzheimer's Disease Patent. This was followed with the announcement of Breast cancer detection drug, PBR. These drugs will add major revenue stream for Samaritan in the very near future.
- SAMARITAN PHARMACEUTICALS has a common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional investor, whereby Fusion Capital agreed to buy $20 million of the Company's common stock providing the corporation with adequate base of financing to carry out its research.
- Strong Management:
The company is headed by Janet Greeson; PhD has been the Company's Chief Executive Officer. Dr. Greeson is a well known Psychologist and author, and has appeared on numerous radio and TV shows. She has been an executive in the healthcare business for over 25 years and founded, grew and merged over 20 companies, which were acquired by Columbia/HCA (NYSE: COL). Dr. Vassilios Papadopoulos, Ph.D. has been Chief Scientific Officer and a Director of the Company since April 2001. Dr. Papadopoulos currently heads the Division of Hormone Research and is Professor of Cell Biology, Pharmacology and Neuroscience at Georgetown University Medical Center. Achievements by Dr. Papadopoulos include the Gold Medal from the City of Athens for Outstanding Performance in Secondary Education, Sandoz Award, Endocrine Society of Australia (1998), James Shannon Director's Award from NIDDK, NIK (1991-1993), and Research Career Development Award, NICHD, NIH (1993-1998).
- Company's stock is at or about the 52 weeks low making it attractive for investment. We only see an upside on this one.
If you want to read more about Samaritan, visit our website www.cyber-stock.net.
Please read our disclaimer on this profile on Samaritan.
This message is sent in compliance of the new e-mail bill section 301. Per section 301, Paragraph (a) (2) (C) of S. 1618, further
transmissions to you by the sender of this e-mail will be stopped at no cost to you. This message is not intended for residents in the state
of WA, NV, CA & VA. Screening of addresses has been done to the best of our technical ability. If you are a Washington, Virginia or California
resident please remove yourself. We respect all removal requests.
To discontinue receipt of further notice and to be removed from our database, please go to the bottom of this email and click on the link to unsubscribe. Any attempts to disrupt the removal e-mail address etc., will not allow us to be able to retrieve and process the removal requests.
To be unsubscribed from the mailing list, simply click on the link below:
|[Prev in Thread]||Current Thread||[Next in Thread]|